Fleet Glycerin Suppositories Adult rectal Uses, Side Effects & Warnings

Print

Save

Generic name: glycerin (rectal) [ GLISS-er-in ]
Brand names: Fleet Glycerin Suppositories Adult, Fleet Glycerin Suppositories Pediatric, Pedia-Lax Liquid, Sani-Supp
Drug class: Laxatives

Medically reviewed by Drugs.com on Sep 13, 2022. Written by Cerner Multum.

What is Fleet Glycerin Suppositories Adult rectal?

Fleet Glycerin Suppositories Adult rectal is used as a laxative. It works by causing the intestines to hold more water, which softens the stool.

Fleet Glycerin Suppositories Adult rectal is used to treat occasional constipation or to cleanse the bowel before a rectal exam or other intestinal procedure.

Fleet Glycerin Suppositories Adult rectal may also be used for purposes not listed in this medication guide.

Warnings

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

Before taking this medicine

You should not use Fleet Fleet Glycerin Suppositories Adult Suppositories Adult if you are allergic to Fleet Glycerin Suppositories Adult.

To make sure Fleet Glycerin Suppositories Adult rectal is safe for you, tell your doctor if you have:

• nausea, vomiting, or stomach pain;

• rectal bleeding;

• a change in bowel habits that has lasted for 2 weeks or longer;

• ulcerative colitis, toxic megacolon; or

• if you have used another laxative for longer than 1 week.

FDA pregnancy category C. It is not known whether Fleet Glycerin Suppositories Adult rectal will harm an unborn baby. Do not use this medicine without a doctor’s advice if you are pregnant.

It is not known whether glycerin rectal passes into breast milk or if it could harm a nursing baby. Do not use this medicine without a doctor’s advice if you are breast-feeding a baby.

When using this medication in any child, use only the forms that are specially made for children. Certain brands of Fleet Glycerin Suppositories Adult rectal should not be used in children.

Do not use Fleet Glycerin Suppositories Adult rectal in a child younger than 2 years old without the advice of a doctor.

How should I use Fleet Glycerin Suppositories Adult rectal?

Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Overuse of a laxative may cause damage to the nerves, muscles, or tissues in your intestines.

Do not take a rectal suppository by mouth. It is for use only in your rectum.

Wash your hands before and after using a rectal enema or suppository.

This medicine comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.

To use the suppository:

• Remove the wrapper before inserting the suppository. Avoid handling the suppository too long or it will melt in your hands.

• Use your finger or the applicator provided to insert the suppository.

• Lie on your left side with your lower leg straight and your upper leg bent. Gently insert the suppository pointed tip first into your rectum, about 1/2 inch for a child or 1 inch for an adult.

• For best results, stay lying down for a few minutes. The suppository will melt quickly and you should feel little or no discomfort while holding it in.

To use the enema:

• Remove the protective shield before inserting the enema tip.

• Lie on your left side with your lower leg straight and your upper leg bent. If giving this medicine to a child, have the child kneel on the floor and then lower the chest forward until the side of the child’s face is resting on the floor.

• Gently insert the tip of the applicator or bulb syringe into the rectum, pointing it toward your navel (belly button). Do not force the applicator into the rectum or injury could result.

• Slowly squeeze the bottle or bulb until it is nearly empty.

For best results after using Fleet Glycerin Suppositories Adult rectal, stay lying down until you feel the urge to have a bowel movement. This medicine should produce a bowel movement within 15 to 60 minutes after using the suppository.

Do not use Fleet Glycerin Suppositories Adult rectal more than once in a 24-hour period.

Call your doctor if this medication does not cause you to have a bowel movement within 1 hour after use.

Store the rectal enema at room temperature away from moisture and heat. Keep the bottle tightly closed when not in use.

Store the rectal suppositories at cool room temperature away from moisture and heat. Some suppositories can be refrigerated. Check your medicine label to be sure how to store your medicine.

What happens if I miss a dose?

Since Fleet Fleet Glycerin Suppositories Adult Suppositories Adult is usually given only once as needed, you will not be on a dosing schedule. Do not use Fleet Fleet Glycerin Suppositories Adult Suppositories Adult rectal more than once in a 24-hour period.

What happens if I overdose?

An overdose of Fleet Glycerin Suppositories Adult rectal is not expected to be dangerous. Seek emergency medical attention or call the Poison Help line at 1-800-222-1222 if anyone has accidentally swallowed the medication.

What should I avoid while using Fleet Glycerin Suppositories Adult rectal?

Avoid using other laxatives in combination with Fleet Glycerin Suppositories Adult rectal unless your doctor has told you to.

Fleet Glycerin Suppositories Adult rectal side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Fleet Glycerin Suppositories Adult rectal may cause serious side effects. Stop using Fleet Glycerin Suppositories Adult rectal and call your doctor at once if you have:

Common side effects of Fleet Glycerin Suppositories Adult may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Fleet Glycerin Suppositories Adult rectal?

Other drugs may interact with glycerin rectal, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.

More about Fleet Glycerin Suppositories Adult (glycerin)

• Check interactions
• Compare alternatives
• Reviews (9)
• Side effects
• Dosage information
• During pregnancy
• Drug class: laxatives
• En español

Patient resources

Other brands

Pedia-Lax Liquid Glycerin Suppositories, Sani-Supp, Fleet Glycerin Suppositories Pediatric

Professional resources

• Prescribing Information

Related treatment guides

• Constipation

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright 1996-2023 Cerner Multum, Inc. Version: 1.04.

The Use of Glycerol Suppositories

%PDF-1.4
%
1 0 obj
>
endobj
2 0 obj
>
endobj
3 0 obj
>
stream
application/pdf

uuid:dbddbafd-1a23-404e-a3d5-9cc667091574uuid:c6e6a19b-bcab-4913-98ff-59de99a2ba7ePDF-XChange Office Addin2021-05-10T09:09:56+01:002021-05-10T09:10:02+01:00PDF-XChange Standard (8.0 build 336) [GDI] [Windows 10 Enterprise x64 (Build 17763)]PDF-XChange Standard (8.0 build 336) [GDI] [Windows 10 Enterprise x64 (Build 17763)]

endstream
endobj
4 0 obj
>
endobj
5 0 obj
>
>>
/Type /Page
>>
endobj
6 0 obj
>
/XObject >
>>
/Type /Page
>>
endobj
7 0 obj
>
stream
xڥXێ}[$`[o ff}A&EJE9UEAvb. fo9{o`7TܸDoE ”ޙe)qj[e FE O”q.Z[&wJSŃaTHj%@u.ZpFDmf;[ZBPUoGZvF(;,i~ѦSfUmU`CHuz=grǗ+ ъB3n\쇻5tl &~jg0.S?uNF5qNr4@9 ְҾRsXMs’lW7%F](31vt**CgyW”

Questions and answers – Genferon Light suppositories

What are the fundamental differences between drops and suppositories containing interferon? Is the effect identical when using them?

Intranasal preparations of IFN α-2b have a predominantly local effect, limited mainly to the nasal mucosa. The systemic effect of intranasal agents is extremely insignificant. Interferon in the form of drops or spray fights ARVI pathogens directly in the primary focus of infection, preventing further massive penetration of viruses into the body. Also, intranasal agents have a local immunomodulatory effect, affecting immune factors and cells of the mucous membrane of the upper respiratory tract. The use of interferon-based intranasal agents is advisable for prophylactic purposes (for example, as a seasonal or post-exposure prophylaxis of influenza and SARS), as well as treatment for SARS limited to local symptoms (runny nose, nasal congestion, etc. ).

The use of suppositories provides a systemic effect of interferon. Being absorbed from the surface of the rectal mucosa and entering the general circulation, interferon alpha-2b has a systemic immunomodulatory effect and an antiviral effect on pathogens circulating in the blood. Thus, the use of interferon in the form of suppositories is advisable, incl. with SARS, accompanied not only by local symptoms, but also by general ones (weakness, malaise, fever, etc.).

Much is written that interferon is not absorbed by rectal administration, is this true?

With rectal administration of the suppository, there is a high bioavailability of interferon (more than 80%), in connection with which a pronounced systemic effect of the drug is ensured. The achievement of the maximum concentration of interferon alpha-2b in the blood serum with rectal administration of GENFERON ^® LIGHT 125 thousand IU candles is recorded already 5 hours after their application. In the study of Korsunsky V. N. the level of IFN-α in the blood after rectal administration was practically not inferior to the injection method of administration ¹ .

Korsunsky V.N. Bruskin A.B. Denisov L.A. Ivanov R.A. Comparative study of the pharmacokinetics of various dosage forms of interferon-alpha-2b // Effective pharmacotherapy. Obstetrics and Gynecology” No. 1. 2007.

Why do the manufacturers of different suppositories differ in the dosage of interferon? Is it true that a higher dosage can provide better results? alpha 2b in three dosages:

– 125,000 IU
– 150,000 IU
– 500 thousand IU.

The different content of the dose of interferon is largely due to the presence of additional components in the composition of a particular drug. The fact is that IFN α-2b can reduce its activity and even be destroyed in inflammatory foci under conditions of oxidative stress. To preserve the activity of interferon, some manufacturers include special antioxidant substances in the composition of the drug, which ensure the stability of the interferon molecule.

For example, in the composition of suppositories GENFERON ^® LITE 125 thousand IU, interferon protection is provided by TAURINE. The presence of TAURINE in the composition of suppositories GENFERON ^® LIGHT 125 thousand IU allows the use of a lower dosage of interferon alfa-2b without any loss in the therapeutic properties of the drug. According to the results of individual studies, this combination allows you to achieve even better therapeutic results in comparison with drugs containing higher doses of interferon.

So, in the studies of Gorelov A.V. et al. ^1.2 in children who were administered suppositories GENFERON ^® LITE 125 thousand IU, there was a lower incidence of nasal congestion, swelling of the tonsils, pathological discharge from the nose, symptoms of pharyngitis and tonsillitis compared with suppositories containing IFN α-2b in dose of 150 thousand IU. The frequency of disappearance of viruses during treatment was 33% higher in the group of patients treated with GENFERON ^® LIGHT suppositories 125 thousand IU

In another study ³ comparing suppositories GENFERON ^® LITE 125 thousand IU with suppositories containing interferon alfa-2b at a dosage of 500 thousand IU in combination with an immunoglobulin complex, therapeutic indicators of GENFERON ^{® 90 012 LITE 125 thousand IU was not only not inferior to the reference drug, but was accompanied by an even more pronounced tendency to stop inflammatory changes and intoxication phenomena, contributed to the rapid normalization of stool in patients with acute intestinal infections and reduced the need for infusion therapy.}

In addition, it is also important to note that a lower dosage of interferon alfa-2b helps to reduce the total interferon load and provides a more gentle attitude towards the baby’s body.

Gorelov A.V., Tselipanova E.E., Alimova I.L. The use of the drug GENFERON ^® LITE in children of different ages with ARVI. effective pharmacotherapy. 2016. No. 21. P. 12-16.

Gorelov A.V., Feklisova L.V., Gracheva N.M., Kanner E.V., Pogorelova O.O., Tselipanova E.E., She Yu.F., Chernyaeva E.V. Immunotropic therapy of acute respiratory viral infections in pediatric practice: experience in the clinical use of interferon-α preparations. Pediatrics. Supplement to Consilium Medicum. 2010. No. 1. S. 72-80.

Gorelov AV, Feklisova LV, Ploskireva AA, Meskina ER, Litvinchuk OA, Chernyaeva EV. Complex therapy of viral diarrhea in children – the first results of an open comparative randomized clinical trial of interferon preparations. Pediatric pharmacology. 2011;8(4):106-14.

What is the difference between GENFERON

^® LIGHT suppositories and preparations based on release-active components?

Preparations based on release-active components are immunomodulatory agents. The principle of their action is based on the stimulation of the child’s body to produce its own interferons. At the same time, the rate of production of endogenous interferons by the body, as well as the amount of interferon formed, is unpredictable, since it depends on the individual characteristics of the immune system – its current status and reactivity (ability to respond to external stimulation). Given the immature immune systems of young children, it is even more difficult to predict the effect of such drugs in infants and newborns.

Suppositories GENFERON ^® LITE 125 thousand IU contain a clearly adjusted dosage of ready-made interferon, which implements immunomodulatory and antiviral activities upon reaching peak blood concentrations. This allows you to optimize and reduce the time that the body can spend on the production of its own endogenous interferons. Rapid blocking of virus activity is the key to a less severe course of a cold and a factor that helps reduce the risk of developing complications of influenza and SARS.

What exactly is the difference between human and recombinant interferon? How exactly is it obtained? Could it affect genetics?

Human leukocyte interferon preparations are made directly from donated blood components. In their composition, these drugs are a mixture of interferon alpha-2b and other cytokine proteins produced by donor blood leukocytes in response to exposure to the virus. The composition of human leukocyte interferon preparations is not constant even from one manufacturer.

The disadvantages of IFN preparations derived from human blood, in addition to the heterogeneity of the composition, also include a low degree of purification, including from viral particles. In addition, human leukocyte IFN preparations cannot be used by injection (intramuscular or intravenous). Currently, leukocyte IFN preparations are used strictly for health reasons, when the expected benefits outweigh the possible risks.

Recombinant interferons are obtained using modern methods of biotechnology and genetic engineering. Synthesis of interferons is produced by special bacteria (E. coli) without the use of donor blood. Thus, an especially pure homogeneous recombinant IFN protein is obtained, identical to the human in amino acid composition. Domestic recombinant IFN alfa-2b was created in 1986–1990 Clinical trials and long-term experience of registered preparations based on recombinant IFN did not reveal significant side effects and contraindications for the use of preparations of recombinant IFN α-2b.

For the first time, the possibility of synthesizing drugs in E. Coli (E. coli) cells was demonstrated more than 40 years ago. In this way, such important drugs as somatostatin and human insulin were obtained. The beginning of the era of biopharmaceuticals can be considered 1982, when the industrial production of recombinant human insulin began. Today, the biopharmaceutical market includes hormones, interferons, interleukins, growth factors, tumor necrosis factors, blood coagulation factors, thrombolytic drugs, enzymes, monoclonal antibodies and vaccines. In addition, recombinant proteins are used to treat, prevent and diagnose various diseases, including: diabetes, multiple sclerosis, hepatitis B and C, anemia, thrombocytopenia, rheumatoid arthritis, Crohn’s disease, malignant neoplasms, etc.

Padkina M.V., Sambuk E.V. Genetically Modified Microorganisms as Producers of Biologically Active Compounds // Ecological Genetics. 2015. V. 13. No. 2. S. 36-57

Do drugs like GENFERON

^® LIGHT suppress the child’s own defenses with frequent use. Will the child’s body subsequently be able to produce interferon normally on its own?

The main stages of development and maturation of the immune system occur before about 5 years of age ⁶ . Children under the age of 5 years, especially in the period up to 2 years, are classified by the CDC and WHO as risk groups for the complicated course of infectious diseases (flu, infectious diarrhea).

Interferon deficiency is typical for young children. In the neonatal period, “early” IFN circulates in the blood of children, which has weak protective properties, unlike interferon-α in an adult ⁷ . In addition, in children under 1 year of age, the synthesis of IFN is reduced by 9 times compared with adults, in children under 3 years of age it is 6 times lower than in adults ⁷ . At an older age, the formation of interferon, as a rule, is reduced in frequently ill children (FIC) and in children with allergic diseases ^2.4 . In addition, viruses are capable of blocking the production of interferon-alpha in the human body ⁵ . IFN, which is also formed in the body during ARVI, is inactivated as a result of oxidative stress caused by inflammation ⁸ .

A decrease in the formation of interferon is fraught with a protracted and complicated course of infection ⁵ . Thus, interferon-alpha preparations play the role of replacement therapy for interferon deficiency.

Denisov LA, Sholokhov IV Discovery of interferon and its clinical application // Infectious Diseases. 2017, No. 1. S. 23–31.

Pugliese A, Salomone C, Martino S, Biglino A, Delpiano A, Tovo PA. Defective interferon-alpha production in children with recurrent respiratory tract infections. A primary or secondary deficiency? Boll East Sieroter Milan. 1985;64(4):328-31.

Vanĕcek K1, Lehovcová A, Hlousková Z. Deficiency of interferon production in children with recurrent respiratory diseases. Czech Med. 1990;13(2-3):64-70.

Edwards MR1, Regamey N, Vareille M, Kieninger E, Gupta A, Shoemark A, Saglani S, Sykes A, Macintyre J, Davies J, Bossley C, Bush A, Johnston SL. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol. 2013 Jul;6(4):797-806.

Tregoning JS1, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. Jan 2010;23(1):74-98.

Teran R1, Miter E, Vaca M, Erazo S, Oviedo G, Hübner MP, Chico ME, Mattapallil JJ, Bickle Q, Rodrigues LC, Cooper PJ. Immune system development during early childhood in tropical Latin America: evidence for the age-dependent down regulation of the innate immune response. Clinic Immunol. 2011 Mar;138(3):299-310.

Zaitseva O.V. Infection and immunity: topical issues in pediatric practice. Children’s infections. 2015. V. 14. No. 1. S. 36-43.

Chebotareva T.A., Zaplatnikov A.L., Zakharova I.N., Vyzhlova E.N. Modern possibilities of interferon therapy for influenza and acute respiratory infections in children. Children’s infections. 2013. V. 12. No. 2. S. 35-38.

Can I use the drug in premature babies?

According to the order of the Ministry of Health of the Russian Federation dated 24.12. 2012 No. 1382n “On approval of the primary health care standard for the prevention of respiratory infections in premature infants”, the use of interferon α-2b with taurine is indicated for the prevention of respiratory infections in premature infants: Interferon alfa-2b + Taurine 250,000 IU / day 7 days (one suppository of 125 thousand IU twice a day with an interval of 12 hours)84 year. This treatment regimen has reduced mortality from neonatal sepsis by 15%. Malinovskaya V.V. studied the therapeutic efficacy of a similar antiviral drug based on interferon in the treatment of severe infections (intrauterine herpes, skin and generalized forms, congenital chlamydia, viral and bacterial pneumonia, meningitis of various etiologies, sepsis, severe forms of pyoinflammatory diseases, visceral candidiasis, mycoplasmosis, cytomegalovirus infection ). The test involved 460 newborns, including premature babies born earlier than 32 weeks (body weight 1421±218) and children born between 33 and 36 weeks of pregnancy (body weight 2086±385). The background conditions of children were edematous syndrome, hyperbilirubinemia, malnutrition, intrauterine growth retardation, hypoxic CNS damage.

Interferon therapy contributed to a more rapid elimination of the symptoms of infectious toxicosis, accelerated weight gain was observed, and improvement of laboratory diagnostic parameters. Against the background of therapy with antiviral immunostimulating drugs of interferon-α, cases of chronic infection and deaths were not recorded. Neurological and purulent-inflammatory complications were observed much less frequently than in the comparison group.

The inclusion of a course of interferon therapy in the complex of therapeutic measures for newborns and premature babies made it possible to reduce the intensity and duration of antibiotic therapy, hormone therapy, and the need for transfusion of blood products. Not a single case of interferon therapy was accompanied by the development of side effects, allergic reactions, or other complications. An analysis of the results of three-year observations did not reveal any differences in the health status of children treated with interferon from the standard indicators of their age group.

At the moment, a clinical study of the use of GENFERON ^® LITE 125 thousand IU in newborns, including those born at different stages of pregnancy, has been completed. The drug can be used in the treatment of various infectious and inflammatory diseases in newborns at a dose of 125,000 IU according to standard therapy regimens.

Optimization of the results of treatment of viral and bacterial infections in children: an algorithm for the use of Kipferon® suppositories | Feklisova L.V., Meskina E.R., Galkina L.A., Tselipanova E.E., Kazakova S.P., Savitskaya N.A.

Optimizing the results of treatment of viral and bacterial infections in children: an algorithm for the use of Kipferon® suppositories

06 April 2009

Share material

print

Add to favorites

• Feklisova L.V.

  1

,

• Meskina E.R.

,

• Galkina L.A.

,

• Tselipanova E. E.

  1

,

• Kazakova S.P.

,

• Savitskaya N.A.

1

GBUZ MO MONIKI them. M.F. Vladimirsky, Moscow, Russia

For citation: Feklisova L.V., Meskina E.R., Galkina L.A. Optimization of the results of treatment of viral and bacterial infections in children: an algorithm for the use of Kipferon® suppositories. breast cancer. 2009;7:468.

Infectious diseases are the most widespread pathology in childhood.